Guanidino compounds
    18.
    发明授权
    Guanidino compounds 失效
    胍基化合物

    公开(公告)号:US07189727B2

    公开(公告)日:2007-03-13

    申请号:US10818187

    申请日:2004-04-05

    摘要: Compounds having the general structure III are provided: where D is N or C; W is selected from Z1, Z2, and Z3 are independently selected from CR8 and N; and the other variables have the values described herein. Compounds of formula III have useful properties for controlling diseases related to MC4-R action in humans including obesity and type II diabetes.

    摘要翻译: 提供具有通式III的化合物:其中D为N或C; W选自Z 1,Z 2,Z 3,Z 3独立地选自CR 8和N; 并且其他变量具有本文所述的值。 式III化合物具有用于控制与包括肥胖和II型糖尿病在内的人类MC4-R作用有关的疾病的有用性质。

    Guanidino compounds
    19.
    发明授权
    Guanidino compounds 失效
    胍基化合物

    公开(公告)号:US06960582B2

    公开(公告)日:2005-11-01

    申请号:US10426937

    申请日:2003-04-30

    摘要: Compounds having the general structure II are provided: A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C═O, C═S, (CR6R7)n, S═O, SO2, O, NR9, S, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n where n is 1, 2, or 3. W is selected from the group consisting of and Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.

    摘要翻译: 提供具有通式II的化合物:A选自C或CH,X和Y独立地选自CH 2,N,CO,CS,(CR SO 2,SO 2,O,NR 9,SO 3,SO 2,SO 2, ,(C) - (CR) - (CR 6) - (CR 6) 其中n为1,2或3.W选自Z 1,...,S 2,...,N 2, Z 2,Z 3,Z 3,Z 3独立地选自取代的碳和氮。 L选自由N,O,S,SO,SO 2,C(O),NC(O),NC(S),OC(O),OC(S) ,C(NR 10),C(NOR 10)和共价键。 式II化合物是黑皮质素-4受体(“MC4-R”)的激动剂,因此可能具有控制人类MC4-R作用相关疾病如肥胖和II型糖尿病的有用性质。

    Guanidino compounds
    20.
    发明授权
    Guanidino compounds 失效
    胍基化合物

    公开(公告)号:US07456183B2

    公开(公告)日:2008-11-25

    申请号:US10474331

    申请日:2002-04-08

    摘要: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.

    摘要翻译: 提供具有一般结构I的化合物。 X和Y独立地选自CH 2,N,NR 9,CO,CS,SO,SO 2,S ,(O) - (CR 6),(O) - (CR 6) C(-S) - (CR 6 R 7)N ,和C(-S) - (CR 6) 其中n为1,2或3.W选自(式I),L选自N,O,SO,SO 2, C(O),NC(O),NC(S),OC(O),OC(S),C(NR 10) ,和共价键。 Z 1,Z 2,Z 3和Z 3独立地选自取代的碳和氮。 式I化合物是黑皮质素-4受体(“MC-4r2”)的激动剂,因此可能具有控制人类MC-4r作用相关疾病如肥胖和II型糖尿病的有用性质。